Orthros Medical

Executive Summary

Orthros Medical is a Dutch biotechnology company founded in 2016 and headquartered in Raalte, the Netherlands. The company specializes in developing novel therapeutics and diagnostics based on VHH (single-domain antibodies derived from llamas). Its primary focus is on creating new local treatments for osteoarthritis in both human and animal health. Leveraging the unique properties of VHH antibodies, Orthros aims to provide targeted, long-lasting therapies with improved efficacy and safety profiles compared to current standards of care. The company's dual approach addresses a significant unmet medical need in osteoarthritis, a degenerative joint disease affecting millions worldwide. Although still in early stages, Orthros Medical's platform technology holds promise for both therapeutic and diagnostic applications, potentially offering a competitive edge in the biotech landscape.

Upcoming Catalysts (preview)

• H2 2026Lead candidate enters preclinical development for osteoarthritis50% success
• 2027Partnership or licensing deal for VHH diagnostic platform30% success
• 2026Series A funding round completion40% success